Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 172 Press Releases
–
02 May 2024
02 May 2024
Ipsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership…
–
24 April 2024
24 April 2024
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
–
22 April 2024
22 April 2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PARIS, FRANCE; BOSTON, U.S., 22 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The…
–
02 April 2024
02 April 2024
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages…
–
15 February 2024
15 February 2024
Your dedicated contacts
-
Amy Wolf
Vice President, Corporate Brand Strategy and Communications
-
-
Ioana Piscociu
Senior Manager, Media Relations
-
Related links
